Years of research by world class scientists
Our Mission
To unlock the benefits of nature and improve the lives of billions
Our Team
The beating heart of Nuritas is our incredibly passionate team.
We have an international team comprising over 16 different nationalities with offices in Dublin and Boston. We are also very proud of our gender balance with 50% women and men across the team.
Our Data Scientists, Biologists, AI Engineers, Chemists, Commercial and Operations teams bring innovation, passion and flexibility to their work every day.
860
Years of cumulative research experience
593
Peer reviewed papers published
65
Patents issued or pending
Our history
- Nuritas Founded2014
- Nuritas raises $5M in seed capital2016Full integration of AI system and wet lab
- $20M raised through Series A2017Collaboration with BASF
Johnson & Johnson innovation award
- Collaboration with Nestle2019Launch of PeptAIde, first AI discovered health product
- Launch of Nuritas ingredient product range2020
- $45M raised through Series B2021Collaboration with Sumitomo Chemical
Our Teams
Advisory Board
Prof Siegel is a leading expert in methods that can rapidly and reliably discover novel enzyme catalysts, which has led to the discovery of enzymes with momentous functions including treating celiac disease and fighting anthrax infections. By leveraging breakthroughs form the field of synthetic biology, Prof Seigel’s research team are capable experimentally evaluating the properties of in silico designed proteins. His awards and honours include National Academies Education Fellowship, Alfred P. Sloan Research Fellowship and has served as the acting Director Innovation Institute for Food and Health, UC Davis.
Throughout his illustrious, 40 year research career, Prof German’s pivotal research has focused on improving foods and their ability to positively impact on health, using milk as the genetic blueprint for how foods can support health. During his career, he has been named to the Most Highly Cited Scientists List by ISI Index and has received honours including the president’s Award Canadian Federation of Biological Societies, John E Kinsella endowed chair University of California and Mention D’Honneur Du Jury ACADEMI MORIM.
Currently a Board Member at Amazon, Mrs. Nooyi was the former Chief Executive Officer of PepsiCo, Inc., from October 2006 to October 2018, where she also served as the Chairman of its board of directors from May 2007 to February 2019. Having joined PepsiCo. in 1994, she held numerous positions including Chief Financial Officer and roles corporate strategy and development, and strategic planning. She has been regularly listed among the World's 100 most influential women.
William W. Li, MD, is a world-renowned physician, scientist, speaker, and author of Eat To Beat Disease – The New Science of How Your Body Can Heal Itself. He is best known for leading the Angiogenesis Foundation. His groundbreaking work has impacted more than 70 diseases including cancer, diabetes, blindness, heart disease, and obesity. His TED Talk, “Can We Eat to Starve Cancer?” has garnered more than 11 million views, and he has appeared on: Good Morning America, CNN, MSNBC, NPR, Voice of America; and in The Atlantic, TIME, and The New York Times. An author of over 100 scientific publications in leading journals such as Science, the New England Journal of Medicine, and The Lancet, Dr. Li has served on the faculties of Harvard Medical School, Tufts University, and Dartmouth Medical School.
Joerg is a career veteran of the consumer and animal health arena having spent over 40 years at Bayer. During his tenure with Consumer Health he held positions as commercial head where he oversaw all sales and marketing activities in EU, Asia-Pacific, as well as Latin America, and was responsible for over €3 billion in annual revenues as well as the acquisition of a plant-based OTC company. Joerg was an executive board member of the consumer health division and lead the go-to-market council on worldwide activities.
Dr. Guru Ramanathan is a globally recognized expert in healthcare innovation and commercialization. He brings a wealth of experience from the clinical, consumer health, animal health and retail sectors. His most recent appoint was as Chief Innovation Officer for GNC, where he spent 15 years leading the development and launch of all products. He previously held senior executive positions at Nutricia (Danone) and Scotia Pharmaceuticals. Guru is very active in nutrition industry initiatives and specialises in Clinical Trials Management, Consumer Health Product Development, DSHEA Regulatory Compliance, Management of Technology in Healthcare and Change Management.
Board
Nora is a mathematician with a PhD in Molecular Evolution and Bioinformatics. Nora’s research has focused primarily on protein evolution and comparative genomics.
Some of Nora’s publications have been placed in a library of the top 2% of published articles in the fields of biology and medicine.
Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms.
Previous to Nuritas™, Nora was the first scientist to show gene transfer between multi-cellular species. This groundbreaking find put into question many of the phylogenetic methods currently in use today.
Nora has developed a multitude of innovative software throughout her research career that are used to this day by research institutes and companies in over 70 countries. Nora has led international research teams around the world, in both academic and industrial settings, and has a proven record in new health-benefiting molecule discovery and commercialisation.
Over the next few years, Nora plans to lead the Nuritas™ team in their goal of reaching billions of people with their life-changing ingredients.
Dr. Guru Ramanathan is a globally recognized expert in healthcare innovation and commercialization. He brings a wealth of experience from the clinical, consumer health, animal health and retail sectors. His most recent appoint was as Chief Innovation Officer for GNC, where he spent 15 years leading the development and launch of all products. He previously held senior executive positions at Nutricia (Danone) and Scotia Pharmaceuticals. Guru is very active in nutrition industry initiatives and specialises in Clinical Trials Management, Consumer Health Product Development, DSHEA Regulatory Compliance, Management of Technology in Healthcare and Change Management.
Matthieu has over 25 years of experience in investment management with a concentration on Asian regions. Matthieu’s investment experience has been centred primarily on thematic investing where he has successfully identified specific themes and designed strategies to profit from them. In mid-2012, Matthieu started to explore the imbalance created by China in the world market of animal protein. He quickly became convinced that it was the tipping point of a multi-decade investment opportunity. In late 2013-early 2014, Matthieu decided to concentrate solely on this and founded New Protein Capital (NPC). The scope of investment of NPC has since been expanded to include the multiple challenges of the food and feed production processes.
Prior to founding NPC in 2014, Matthieu was with Everest Capital, a large independent investment firm with offices in the US and in Singapore, for over 16 years. At Everest Capital, he was a Senior Managing Director and the Director of Research as well as a member of the Executive and Investment committees. Prior to Everest, Matthieu was with Banque Paribas, in Hong Kong, New York, Taipei and Paris.
Nick Rosa is Co-founder and Managing Director of Sandbox Industries and Managing Director of Cultivian Sandbox. Nick serves as a Director or advisor to several companies, such as the Blue Cross Blue Shield Venture Fund, Healthbox Global Partners, Oncology Analytics, Nuritas, TechStars Chicago and The Chicago Innovation Awards.
Prior to forming Sandbox, Nick led the buyout and served as CEO of The NutraSweet Company. As a senior executive at Monsanto, he led the Nutrition and Consumer Products division, overseeing NutraSweet, the consumer Lawn and Garden Business, and Kelco food ingredients business. Nick also served as a Senior Vice President and Advisor to the Board of Directors at Monsanto.
Previously, Nick held senior executive positions at Searle and has experience with Masonite Corporation and Baxter. He has lived and worked in several countries, including Kuwait, Switzerland and France. Nick has also been involved with numerous civic and commercial organizations. Nick holds a B.S. in Political Science from Northern Illinois University and an MBA from DePaul University.
Matthieu has a postgraduate degree in Corporate Finance from Université Paris Dauphine and has a graduate degree from Institut d’Etudes Politiques de Paris (Sciences Po).
Prior to forming Sandbox, Nick led the buyout and served as CEO of The NutraSweet Company. As a senior executive at Monsanto, he led the Nutrition and Consumer Products division, overseeing NutraSweet, the consumer Lawn and Garden Business, and Kelco food ingredients business. Nick also served as a Senior Vice President and Advisor to the Board of Directors at Monsanto.
Previously, Nick held senior executive positions at Searle and has experience with Masonite Corporation and Baxter. He has lived and worked in several countries, including Kuwait, Switzerland and France. Nick has also been involved with numerous civic and commercial organizations. Nick holds a B.S. in Political Science from Northern Illinois University and an MBA from DePaul University.
Matthieu has a postgraduate degree in Corporate Finance from Université Paris Dauphine and has a graduate degree from Institut d’Etudes Politiques de Paris (Sciences Po).
Stephan joined the Grosvenor Food & AgTech (formerly known as Wheatsheaf Group) Board as a Non-Executive Director in May 2017. Since then, he has assumed increasing responsibilities within the Group, becoming a full time Executive Director in January 2019.
Stephan has worked with entrepreneurial growth companies since the 1980s. He has been a private equity investor since 1999, investing in software, communications technology, biotechnology, clean energy and agricultural businesses. He led VantagePoint Capital Partners' $1Bn CleanTech Fund from its inception. More recently he served as a senior advisor in forming the Breakthrough Energy Ventures fund and was the Managing Partner of Resourcient Group LLC. Stephan has also acted as co-founder of several companies and has helped "raise" five "unicorn" companies reaching valuations of between $1 and $100bn.
Stephan is a graduate of the School of Architecture at the University of Virginia (BCP) and the University of Virginia School of Law (JD).
Randall has assisted companies in accessing capital as founder of Exodus Commercial Capital and has served as its President since 2013. He has over 30 years of finance and operations experience that includes Fortune 50 companies such as GE Capital, Wells Fargo and Anthem. Randall has held various executive leadership roles, including: Executive Vice President and Chief Compliance Officer, Executive Vice President and Chief Auditor and Managing Director of Corporate Development. His experience includes the closing of several mergers and acquisitions for over $2B. He also served as CEO for a start-up logistics firm, s2f worldwide, LLC; that was sold to a Fortune 500 company.
He obtained his Bachelor of Science degree in General Management/Accounting and MBA in Finance from Purdue University.
Team
Nora is a mathematician with a PhD in Molecular Evolution and Bioinformatics. Nora’s research has focused primarily on protein evolution and comparative genomics.
Some of Nora’s publications have been placed in a library of the top 2% of published articles in the fields of biology and medicine.
Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms.
Previous to Nuritas™, Nora was the first scientist to show gene transfer between multi-cellular species. This groundbreaking find put into question many of the phylogenetic methods currently in use today.
Nora has developed a multitude of innovative software throughout her research career that are used to this day by research institutes and companies in over 70 countries. Nora has led international research teams around the world, in both academic and industrial settings, and has a proven record in new health-benefiting molecule discovery and commercialisation.
Over the next few years, Nora plans to lead the Nuritas™ team in their goal of reaching billions of people with their life-changing ingredients.
A fellow of the Chartered Association of Certified Accountants, Owen has 20+ years experience in FMCG with extensive fund-raising and M&A experience.
Owen joined Nuritas in 2020, having spent the previous 5 years as CFO of a Global eCommerce and AI Technology start-up. Prior to that, he was CFO of an international FMCG business with customers such as Tesco, M&S, Aldi and Lidl. He also served time as the Finance Director of an IT multinational services company with major global customers such as Dell, Intel and Apple.
Owen has an MBA from Dublin City University and also completed the Stanford Graduate School of Business Strategic Leadership for CFO's programme.
Owen has negotiated Long Term Agreements with some of the largest Technology and Retail Companies in the world and has extensive M&A and fundraising experience to fund global growth.
Bernard Keogh has over 25 years’ experience in the technology and communications industries.
Prior to joining Nuritas, Bernard was a senior adviser at Granahan McCourt, a private investment firm focused on connecting people to innovation in technologically underserved areas of the world. He served as General Counsel of enet, the leading wholesale communications provider in Ireland, and sat on the boards of several other entities in which Granahan McCourt held investments.
Previously, Bernard held leadership roles with global communications firms Level 3 and Global Crossing. He was General Counsel at ComReg, regulator of the communications and postal sectors in Ireland, and held various roles at William Fry, a leading international law firm.
Neil has 20 years of experience across a wide range of commercial functions in the food, nutrition and consumer health industries. He has been responsible for a number of global-first-to-market launches, including novel health-promoting ingredients via some of the world’s largest food manufacturers and consumer health CPGs; but also branded D2C products both through eCommerce and traditional bricks-and-mortar retail. Combining a degree in Nutritional Science with a business education from world renown Henley Business School, Neil’s fascination is the intersection of technology, food and genomics and how these will converge to disrupt the traditional (and failing) healthcare model.
Investors
Ali Partovi
Bono
Edge
